<DOC>
	<DOCNO>NCT02125019</DOCNO>
	<brief_summary>Longitudinal Evaluation Taxane induce neuropathy early stage breast cancer .</brief_summary>
	<brief_title>Longitudinal Evaluation Taxane Induced Neuropathy Early Stage Breast Cancer</brief_title>
	<detailed_description>A study assess feasibility evaluate neuropathy symptom prospectively use test gate balance parameter .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<criteria>Inclusion criterion Patients ( men woman ) diagnose breast cancer stag IIII initiate first line adjuvant neoadjuvant therapy paclitaxel docetaxel Ability understand willingness sign write informed consent document . Patients functional limitation due musculoskeletal condition include , condition know remain stable relatively short duration study . Concurrent standard investigational agent permissible standard chemotherapy drug . Exclusion Criteria Prior know chemotherapy target therapy ( breast cancer malignancy know associate neuropathy last 12 month ( platinum therapy , bortezomib , vinblastine , etc . ) Prior taxane exposure time Preexisting know diagnosis type neuropathy prior start paclitaxel docetaxel chemotherapy Pregnant nursing woman . Unable give inform consent . Preexisting low extremity amputation Inability walk stand without assistance due condition Neuropathic pain medication prior start study include gabapentin , pregabalin , amytriptyline , duloxetine ( initiation neuropathic pain medication treatment permissible ) Patients need ambulatory assist device Back low extremity surgery last 6 month Back low extremity surgery timepoint interferes gait balance per patient provider report</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Taxane</keyword>
	<keyword>Gait</keyword>
	<keyword>Men</keyword>
	<keyword>Women</keyword>
</DOC>